File Download
There are no files associated with this item.
Supplementary
-
Citations:
- Appears in Collections:
Conference Paper: A novel oral chemoprophylactic agent for venous thromboembolism after Total Knee Arthroplasty - is it safe?
Title | A novel oral chemoprophylactic agent for venous thromboembolism after Total Knee Arthroplasty - is it safe? |
---|---|
Authors | |
Issue Date | 2013 |
Publisher | Hong Kong Academy of Medicine Press. |
Citation | The 33rd Annual Congress of the Hong Kong Orthopaedic Association (HKOA 2013), Hong Kong, China, 23-24 November 2013. In Conference Abstracts, 2013, p. 76, abstract no. 9.3 How to Cite? |
Abstract | Introduction: Venous thromboembolism and postoperative wound drainage and subsequent infection are both serious
complications after primary total knee arthroplasty (TKA). The balance between bleeding and clotting is a dilemma. Newer
agents include direct factor Xa inhibitor is quoted to have superior efficacy to prevent deep vein thrombosis compared
with low-molecular-weight heparin without increasing side-effect of major blood loss. This study aimed to examine the
safety profile of a novel factor Xa inhibitor (Apixaban) used in Chinese patients.
Materials and Methods: A total of 40 consecutive patients (8 male and 32 female) with a mean age of 73.6 (range, 54-
84) years requiring unilateral TKA were recruited. Twenty patients received a course of 2-week 2.5 mg Apixaban twice
daily as chemoprophylaxis. The wound condition, soaking of gauze, swelling of the limb, perioperative haemoglobin and
haematocrit, renal function, C-reactive protein, thromboembolism, and bleeding complication were documented. Another
20 patients undergoing a course of 2-week 300 mg aspirin daily as chemoprophylaxis were compared.
Results: Preoperative mechanical alignment of both groups was comparable. The drain output, frequency of wound
dressing, and soaking of dressing between the groups were comparable. There was neither thromboembolism nor bleeding
complications. Both groups showed a sustained and comparable increase in haemoglobin and haematocrit and stable renal
function. There was no surgical site infection.
Discussion and Conclusion: The early experience using Apixaban as chemoprophylaxis in TKA is safe. Longer period of
use of the drug is required to monitor its efficacy and safety. |
Description | Conference Theme: Defying the Aging Spine Concurrent Free Papers 9: Hips and Knees 2 |
Persistent Identifier | http://hdl.handle.net/10722/204335 |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ng, FY | en_US |
dc.contributor.author | Fu, CHH | en_US |
dc.contributor.author | Yan, CH | en_US |
dc.contributor.author | Chan, PK | en_US |
dc.contributor.author | Chiu, PKY | en_US |
dc.date.accessioned | 2014-09-19T22:41:15Z | - |
dc.date.available | 2014-09-19T22:41:15Z | - |
dc.date.issued | 2013 | en_US |
dc.identifier.citation | The 33rd Annual Congress of the Hong Kong Orthopaedic Association (HKOA 2013), Hong Kong, China, 23-24 November 2013. In Conference Abstracts, 2013, p. 76, abstract no. 9.3 | en_US |
dc.identifier.uri | http://hdl.handle.net/10722/204335 | - |
dc.description | Conference Theme: Defying the Aging Spine | - |
dc.description | Concurrent Free Papers 9: Hips and Knees 2 | - |
dc.description.abstract | Introduction: Venous thromboembolism and postoperative wound drainage and subsequent infection are both serious complications after primary total knee arthroplasty (TKA). The balance between bleeding and clotting is a dilemma. Newer agents include direct factor Xa inhibitor is quoted to have superior efficacy to prevent deep vein thrombosis compared with low-molecular-weight heparin without increasing side-effect of major blood loss. This study aimed to examine the safety profile of a novel factor Xa inhibitor (Apixaban) used in Chinese patients. Materials and Methods: A total of 40 consecutive patients (8 male and 32 female) with a mean age of 73.6 (range, 54- 84) years requiring unilateral TKA were recruited. Twenty patients received a course of 2-week 2.5 mg Apixaban twice daily as chemoprophylaxis. The wound condition, soaking of gauze, swelling of the limb, perioperative haemoglobin and haematocrit, renal function, C-reactive protein, thromboembolism, and bleeding complication were documented. Another 20 patients undergoing a course of 2-week 300 mg aspirin daily as chemoprophylaxis were compared. Results: Preoperative mechanical alignment of both groups was comparable. The drain output, frequency of wound dressing, and soaking of dressing between the groups were comparable. There was neither thromboembolism nor bleeding complications. Both groups showed a sustained and comparable increase in haemoglobin and haematocrit and stable renal function. There was no surgical site infection. Discussion and Conclusion: The early experience using Apixaban as chemoprophylaxis in TKA is safe. Longer period of use of the drug is required to monitor its efficacy and safety. | - |
dc.language | eng | en_US |
dc.publisher | Hong Kong Academy of Medicine Press. | - |
dc.relation.ispartof | Annual Congress of the Hong Kong Orthopaedic Association, HKOA 2013 | en_US |
dc.title | A novel oral chemoprophylactic agent for venous thromboembolism after Total Knee Arthroplasty - is it safe? | en_US |
dc.type | Conference_Paper | en_US |
dc.identifier.email | Ng, FY: fyng@hkucc.hku.hk | en_US |
dc.identifier.email | Fu, CHH: drhfu@hku.hk | en_US |
dc.identifier.email | Yan, CH: yanchoi@hku.hk | en_US |
dc.identifier.email | Chan, PK: cpk464@hku.hk | en_US |
dc.identifier.email | Chiu, PKY: pkychiu@hkucc.hku.hk | en_US |
dc.identifier.authority | Yan, CH=rp00303 | en_US |
dc.identifier.authority | Chiu, PKY=rp00379 | en_US |
dc.identifier.hkuros | 235781 | en_US |
dc.identifier.hkuros | 240365 | - |
dc.identifier.spage | 76, abstract no. 9.3 | en_US |
dc.identifier.epage | 76, abstract no. 9.3 | en_US |
dc.publisher.place | Hong Kong | - |